Research programme: therapeutics - Cycle Pharmaceuticals
Latest Information Update: 28 Jun 2024
Price :
$50 *
At a glance
- Originator Cycle Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Deglutition disorders; Dyskinesias
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for research development in Deglutition-disorders in United Kingdom (Transdermal, Patch)
- 28 Jun 2024 No recent reports of development identified for research development in Dyskinesias in United Kingdom (Transdermal, Patch)
- 04 May 2020 Cycle Pharmaceuticals and Medherant agree to develop medicines using the TEPI Patch® technology for Dysphagia and Dyskinesia